<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129619">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02145676</url>
  </required_header>
  <id_info>
    <org_study_id>191622-127</org_study_id>
    <secondary_id>2013-002346-37</secondary_id>
    <nct_id>NCT02145676</nct_id>
  </id_info>
  <brief_title>OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper
      limb spasticity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Elbow Flexors Using a 6-Point Scale</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the MAS-B Score of Shoulder Adductors Using a 6-Point Scale</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Of Overall Change by Physician Compared to Baseline Using a 9-Point Scale</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pain on an 11-Point Scale</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the 19-Item Spasticity Impact Assessment-Upper Limb (SIA-UL) Score</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">423</enrollment>
  <condition>Muscle Spasticity</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>onabotulinumtoxinA Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 1 injected into predefined muscles of the study limb on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onabotulinumtoxinA Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA Dose 2 injected into predefined muscles of the study limb on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>onabotulinumtoxinA</intervention_name>
    <description>OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.</description>
    <arm_group_label>onabotulinumtoxinA Dose 1</arm_group_label>
    <arm_group_label>onabotulinumtoxinA Dose 2</arm_group_label>
    <other_name>BOTOXÂ®</other_name>
    <other_name>botulinum toxin type A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (normal saline)</intervention_name>
    <description>Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.</description>
    <arm_group_label>placebo (normal saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Upper limb spasticity in the elbow and shoulder due to stroke, with the most recent
             stroke at least 3 months ago

        Exclusion Criteria:

          -  Spasticity in the non-study upper limb that requires treatment

          -  Presence of fixed contractures in of the study muscles in elbow or shoulder

          -  Profound atrophy of muscles to be injected

          -  Previous surgical intervention, nerve block, or muscle block for the treatment of
             spasticity in the study limb in the last 12 months

          -  Injection of corticosteroids or anesthetics, use of casting or dynamic splinting or
             constraint-induced movement therapy (CIMT) for the study limb within 3 months

          -  Ultrasound therapy, electrical stimulation, or acupuncture in the study limb within 1
             month

          -  Condition other than stroke contributing to upper limb spasticity

          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral
             sclerosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
